title: Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
abstract: BACKGROUND
  An increase in worldwide HPV vaccination could be facilitated if fewer than three doses of vaccine are as effective as three doses. We originally aimed to compare the immunogenicity and frequency of persistent infection and cervical precancerous lesions caused by vaccine-targeted HPV after vaccination with two doses of quadrivalent vaccine on days 1 and 180 or later, with three doses on days 1, 60, and 180 or later, in a cluster-randomised trial. Suspension of the recruitment and vaccination due to events unrelated to our study meant that some enrolled girls could not be vaccinated and some vaccinated girls received fewer than the planned number of vaccinations by default. As a result, we re-analysed our data as an observational cohort study.
  
  
  METHODS
  Our study was designed to be done in nine locations (188 clusters) in India. Participants were unmarried girls aged 10-18 years vaccinated in four cohorts: girls who received three doses of vaccine on days 1, 60, and 180 or later, two doses on days 1 and 180 or later, two doses on days 1 and 60 by default, and one dose by default. The primary outcomes were immunogenicity in terms of L1 genotype-specific binding antibody titres, neutralising antibody titres, and antibody avidity after vaccination for the vaccine-targeted HPV types 16, 18, 6, and 11 and incident and persistent infections with these HPVs. Analysis was per actual number of vaccine doses received. This study is registered with ISRCTN, number ISRCTN98283094; and with ClinicalTrials.gov, number NCT00923702.
  
  
  RESULTS
  Vaccination of eligible girls was initiated on Sept 1, 2009, and continued until April 8, 2010. Of 21 258 eligible girls identified at 188 clusters, 17 729 girls were recruited from 178 clusters before suspension. 4348 (25%) girls received three doses, 4979 (28%) received two doses on days 1 and 180 or later, 3452 (19%) received two doses at days 1 and 60, and 4950 (28%) received one dose. Immune response in the two-dose HPV vaccine group was non-inferior to the three-dose group (median fluorescence intensity ratio for HPV 16 1·12 [95% CI 1·02-1·23] and for HPV 18 1·04 [0·92-1·19]) at 7 months, but was inferior in the two-dose default (0·33 [0·29-0·38] for HPV 16 and 0·51 [0·43-0·59] for HPV 18) and one-dose default (0·09 [0·08-0·11] for HPV 16 and 0·12 [0·10-0·14] for HPV 18) groups at 18 months. The geometric mean avidity indices after fewer than three doses by design or default were non-inferior to those after three doses of vaccine. Fewer than three doses by design and default induced detectable concentrations of neutralising antibodies to all four vaccine-targeted HPV types, but at much lower concentration after one dose. Cervical samples from 2649 participants were tested and the frequency of incident HPV 16, 18, 6, and 11 infections was similar irrespective of the number of vaccine doses received. The testing of at least two samples from 838 participants showed that there was no persistent HPV 16 or 18 infections in any study group at a median follow-up of 4·7 years (IQR 4·2-5·1).
  
  
  CONCLUSIONS
  Despite the limitations imposed by the suspension of the HPV vaccination, our findings lend support to the WHO recommendation of two doses, at least 6 months apart, for routine vaccination of young girls. The short-term protection afforded by one dose of HPV vaccine against persistent infection with HPV 16, 18, 6, and 11 is similar to that afforded by two or three doses of vaccine and merits further assessment.
  
  
  BACKGROUND
  Bill & Melinda Gates Foundation.
authors.affiliation: Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France. Electronic address: sankarr@iarc.fr.
authors.forename: Rengaswamy
authors.initials: R
authors.lastname: Sankaranarayanan
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Priya Ramesh
authors.initials: PR
authors.lastname: Prabhu
authors.affiliation: Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Pawlita
authors.affiliation: Infections and Cancer Biology Group, Infections Section, International Agency for Research on Cancer, Lyon, France.
authors.forename: Tarik
authors.initials: T
authors.lastname: Gheit
authors.affiliation: Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Neerja
authors.initials: N
authors.lastname: Bhatla
authors.affiliation: Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
authors.forename: Richard
authors.initials: R
authors.lastname: Muwonge
authors.affiliation: Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
authors.forename: Bhagwan M
authors.initials: BM
authors.lastname: Nene
authors.affiliation: Christian Fellowship Community Health Centre, Ambillikai, Tamil Nadu, India.
authors.forename: Pulikottil Okuru
authors.initials: PO
authors.lastname: Esmy
authors.affiliation: Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
authors.forename: Smita
authors.initials: S
authors.lastname: Joshi
authors.affiliation: Mehdi Nawaj Jung Institute of Oncology and Regional Cancer Center, Red Hills, Lakadikapul, Hyderabad, Andhra Pradesh, India.
authors.forename: Usha Rani Reddy
authors.initials: UR
authors.lastname: Poli
authors.affiliation: Health Care Global Cancer Centre, Sola-Science City Road, Near Sola Bridge, Ahmedabad, Gujarat, India.
authors.forename: Parimal
authors.initials: P
authors.lastname: Jivarajani
authors.affiliation: Sir Thodup Namgyal Memorial Hospital/Sikkim Manipal Institute of Medical Sciences, Gangtok, Sikkim, India.
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Verma
authors.affiliation: Civil Hospital, Aizawl, Mizoram, India.
authors.forename: Eric
authors.initials: E
authors.lastname: Zomawia
authors.affiliation: Cancer Foundation of India, Kolkata, West Bengal, India.
authors.forename: Maqsood
authors.initials: M
authors.lastname: Siddiqi
authors.affiliation: Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
authors.forename: Surendra S
authors.initials: SS
authors.lastname: Shastri
authors.affiliation: Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
authors.forename: Kasturi
authors.initials: K
authors.lastname: Jayant
authors.affiliation: Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
authors.forename: Sylla G
authors.initials: SG
authors.lastname: Malvi
authors.affiliation: Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Lucas
authors.affiliation: Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Angelika
authors.initials: A
authors.lastname: Michel
authors.affiliation: Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Butt
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Janki Mohan Babu
authors.initials: JM
authors.lastname: Vijayamma
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Subha
authors.initials: S
authors.lastname: Sankaran
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Thiraviam Pillai Rameshwari Ammal
authors.initials: TP
authors.lastname: Kannan
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Rintu
authors.initials: R
authors.lastname: Varghese
authors.affiliation: Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
authors.forename: Uma
authors.initials: U
authors.lastname: Divate
authors.affiliation: Christian Fellowship Community Health Centre, Ambillikai, Tamil Nadu, India.
authors.forename: Shila
authors.initials: S
authors.lastname: Thomas
authors.affiliation: Gujarat Cancer and Research Institute, M P Shah Cancer Hospital, Civil Hospital Campus, Asarwa, Ahmedabad, India.
authors.forename: Geeta
authors.initials: G
authors.lastname: Joshi
authors.affiliation: Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Willhauck-Fleckenstein
authors.affiliation: Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Tim
authors.initials: T
authors.lastname: Waterboer
authors.affiliation: Tumorvirus-specific Vaccination Strategies, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Müller
authors.affiliation: EMBL-DKFZ Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Sehr
authors.affiliation: Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Solapur District, Maharashtra, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Hingmire
authors.affiliation: Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Alka
authors.initials: A
authors.lastname: Kriplani
authors.affiliation: Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
authors.forename: Gauravi
authors.initials: G
authors.lastname: Mishra
authors.affiliation: Department of Preventive Oncology, Tata Memorial Center, Parel, Mumbai, India.
authors.forename: Sharmila
authors.initials: S
authors.lastname: Pimple
authors.affiliation: Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India.
authors.forename: Radhika
authors.initials: R
authors.lastname: Jadhav
authors.affiliation: Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Sauvaget
authors.affiliation: Infections and Cancer Biology Group, Infections Section, International Agency for Research on Cancer, Lyon, France.
authors.forename: Massimo
authors.initials: M
authors.lastname: Tommasino
authors.affiliation: Rajiv Gandhi Centre for Biotechnology, Poojappura, Thiruvananthapuram, Kerala, India.
authors.forename: Madhavan Radhakrishna
authors.initials: MR
authors.lastname: Pillai
mesh_terms: D000293:Adolescent; D002648:Child; D005260:Female; D006801:Humans; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002584:Cervix Uteri / Q000821:virology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D057239:Early Termination of Clinical Trials; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage; D015994:Incidence; D007194:India / Q000453:epidemiology; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D011446:Prospective Studies; D014611:Vaccination / Q000379:methods; D064166:Vaccine Potency
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18